- Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2024$37.35 (-1.79%)Earnings
- Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2024$39.22 (+18.28%)Earnings
- Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$15.57 (-5.86%)Earnings
- Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call TranscriptJul 25, 2023
- Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call TranscriptJun 15, 2023
- Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call TranscriptFeb 08, 2022
- Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 22, 2021
- Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call TranscriptJun 21, 2021
Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call Transcript
Good day, and welcome to the Revolutionizing Treatment for Demodex Blepharitis Patients Conference Call. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to David Nakasone, Head of Investor Relations. You may begin.
Thank you, Michelle. I would like to draw your attention to Slide 2, which contains our forward-looking language statement. We will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
With that, I'd like to turn the call over to Bobby, our President and Chief Executive Officer. Bobby?
Thank you very much, David. So I'm Bobak Azamian. I'm the CEO of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)